Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176940 · ClinicalTrials.gov registry record · NA
2-HOBA: Initial Evaluation in Humans
A NA study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03176940 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 18 participants.
The verdict
NCT03176940, a NA study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the administration of single doses of 2-HOBA in humans, with an escalation of doses that begins with the calculated Maximum Recommended Starting Dose. This evaluation will assess tolerability to oral administration of 2-HOBA, obtain pharmacokinetic data, characterize the 2-HOBA metabolic pathways, and determine the relation of dose to prevention of formation of bi-functional electrophile adducts in blood. Characterization of the metabolic fate of 2-HOBA will be supported by investigations that evaluate metabolism in microsomes and cells.
Interventions
- DIETARY_SUPPLEMENT 2-HOBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2018-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03176940
The ClinicalTrials.gov registry entry for NCT03176940 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-HOBA is the first listed.
NCT03176940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03176940 about?
NCT03176940 is a clinical study titled "2-HOBA: Initial Evaluation in Humans". The purpose of this study is to evaluate the administration of single doses of 2-HOBA in humans, with an escalation of doses that begins with the calculated Maximum Recommended Starting Dose. This evaluation will assess tolerability to oral administration of 2-HOBA, obtain pharmacokinetic data, char...
What is the current status of trial NCT03176940?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2017-08-02. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT03176940?
The interventions under investigation include: 2-HOBA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03176940?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.